- Home
- INO vs CNTB Comparison
INO vs CNTB Comparison
Compare INO & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INO | CNTB |
|---|---|---|
| Founded | 1979 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 118.9M | 140.4M |
| IPO Year | 1999 | 2020 |
Fundamental Metrics
Financial Performance| Metric | INO | CNTB |
|---|---|---|
| Price | $1.00 | $0.89 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | $3.17 | ★ $5.88 |
| AVG Volume (30 Days) | ★ 2.6M | 1.6M |
| Earning Date | 11-09-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 54.18 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $42,220,086.00 | $64,000.00 |
| Revenue This Year | N/A | $11,291.47 |
| Revenue Next Year | N/A | $74.30 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 19.37 | N/A |
| 52 Week Low | $0.56 | $0.85 |
| 52 Week High | $2.72 | $3.82 |
Technical Indicators
Market Signals| Indicator | INO | CNTB |
|---|---|---|
| Relative Strength Index (RSI) | 37.22 | 38.44 |
| Support Level | $0.56 | $0.85 |
| Resistance Level | $1.24 | $2.74 |
| Average True Range (ATR) | 0.08 | 0.08 |
| MACD | -0.02 | 0.03 |
| Stochastic Oscillator | 12.94 | 3.54 |
Price Performance
Historical ComparisonAbout INO Inovio Pharmaceuticals Inc.
Inovio Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. Its candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP.
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.